Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: A phase 2 trial

Thomas Dipetrillo, Mohan Suntharalingam, Thomas Ng, Jacques Fontaine, Naomi Horiba, Nicklas Oldenburg, Kimberly Perez, Ari Birnbaum, Richard Battafarano, Whitney Burrows, Howard Safran

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE: To evaluate the pathologic complete response (CR) rate and safety of paclitaxel poliglumex (PPX), cisplatin, and concurrent radiation for patients with esophageal cancer. PATIENTS AND METHODS: Patients with adenocarcinoma or squamous cell carcinoma of the esophagus or gastroesophageal junction with no evidence of distant metastasis received PPX (50 mg/m/wk) and cisplatin (25 mg/m/wk) for 6 weeks with 50.4 Gy concurrent radiation. Six to eight weeks after completion of chemoradiotherapy, patients underwent surgical resection. RESULTS: Forty patients were enrolled, 37 patients with adenocarcinoma and 3 patients with squamous cell cancer. The treatment-related grade 3 nonhematologic toxicities included esophagitis (7%), nausea (7%), and fatigue (5%). Three patients with clinical endoscopic CR (2 with squamous cell cancer) refused surgery. Twelve of the remaining 37 patients (32%) had a pathologic CR. The 12 patients with pathologic CR all had adenocarcinoma. CONCLUSION: PPX, cisplatin, and concurrent radiation are well tolerated, easily administered regimen for esophageal cancer with a low incidence of significant esophagitis and a high pathologic CR rate consistent with the preclinical data of PPX and radiation.

Original languageEnglish (US)
Pages (from-to)64-67
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume35
Issue number1
DOIs
StatePublished - Feb 1 2012
Externally publishedYes

Keywords

  • esophageal cancer
  • paclitaxel poliglumex
  • radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: A phase 2 trial'. Together they form a unique fingerprint.

Cite this